精密科學 EXAS 深 滬
已收盤 03-23 16:00:00 美东时间
104.91
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 104.91
- 總市值 2003.78万
- 52周最高 104.98
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 38.8118
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 159.54
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.67
- 每 手 1
- 風險率 23.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Transcript: ResMed Q3 2026 Earnings Conference Call
ResMed (NYSE:RMD) released third-quarter financial results and hosted an earnin...
05-01 05:53
ResMed announces CFO succession
Resmed (RMD) chief financial officer Brett Sandercock will retire effective May 4, 2026. Aaron Bloomer has been appointed CFO following a comprehensive search. Bloomer joins from Exact Sciences, recen...
05-01 04:25
雅培(ABT)股票4月21日盘中下跌3.33%：投资者必看的核心信息
• 雅培第一季度利润和营收均超出预期。 • 由于收购Exact Sciences，公司下调了全年利润指引。 • 监管审查和营养业务部门的下滑令股价承压。
04-21 19:16
Abbott Laboratories Sales Growth Outlook 'Leaves Room For Upside': Analyst
Abbott Labs reported in-line Q1 results. Held growth outlook unchanged despite positive impact of the Exact Sciences acquisition.
04-17 23:55
Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks
Abbott cuts 2026 earnings outlook despite Q1 beat; medical devices strength offset by weaker diagnostics demand and nutrition sales decline.
04-17 00:24
Transcript: Abbott Laboratories Q1 2026 Earnings Conference Call
Abbott Laboratories (NYSE:ABT) released first-quarter financial results and hos...
04-16 22:26
Abbott dips as Exact Sciences buyout hurts outlook
Shares of Abbott Laboratories (ABT) dipped in the premarket on Thursday after the MedTech giant lowered its full-year earnings outlook, indicating an impact from its recent acquisition of cancer diagn...
04-16 20:05
UPDATE 1-Abbott results beat on medical device boost, Exact deal hits forecast
UPDATE 1-Abbott results beat on medical device boost, Exact deal hits forecast Adds shares in paragraph 2, CEO comment in paragraph 4 April 16 (Reuters) - Abbott ABT.N marginally beat Wall Street estimates for quarterly profit and revenue on Thursday, partially helped by its newly acquired cancer di
04-16 19:40
Abbott Laboratories Lowers FY2026 Adj EPS Guidance from $5.55-$5.80 to $5.38-$5.58 vs $5.62 Est
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
04-16 19:36
